Fly News Breaks for March 3, 2020
Mar 3, 2020 | 08:33 EDT
Baird analyst Michael Ulz said Amicus Q4 results showed continued execution while highlighting its strategic priorities and reaffirming its guidance for continued strong Galafold growth in 2020. The company also provided key pipeline updates including its gene therapy pipeline which he believes are underappreciated by investors. Ulz reiterated his Outperform rating and $20 price target on Amicus shares.
News For FOLD From the Last 2 Days
There are no results for your query FOLD